Redhill Biopharma Ltd
RDHL
Company Profile
Business description
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.
Contact
21 Ha’arba’a Street
Tel Aviv6473921
ISRT: +972 35413131
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
35
Stocks News & Analysis
stocks
Picking dividend shares in 2026? Here’s where to look
A new report from Morningstar shows opportunities for income investors.
stocks
Ahead of earnings, is Nvidia a buy, a sell, or fairly valued?
With outstanding long-term estimates, here’s what we think of Nvidia stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,721.40 | 31.90 | -0.36% |
| CAC 40 | 7,967.93 | 151.09 | -1.86% |
| DAX 40 | 23,180.53 | 409.99 | -1.74% |
| Dow JONES (US) | 46,091.74 | 498.50 | -1.07% |
| FTSE 100 | 9,552.30 | 123.13 | -1.27% |
| HKSE | 25,784.05 | 145.98 | -0.56% |
| NASDAQ | 22,432.85 | 275.23 | -1.21% |
| Nikkei 225 | 48,621.76 | 81.22 | -0.17% |
| NZX 50 Index | 13,326.90 | 15.92 | -0.12% |
| S&P 500 | 6,617.32 | 55.09 | -0.83% |
| S&P/ASX 200 | 8,447.90 | 35.60 | -0.42% |
| SSE Composite Index | 3,944.04 | 4.22 | 0.11% |